A5056881595- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Breast Cancer Treatment Studies
- Radiomics and Machine Learning in Medical Imaging
- BRCA gene mutations in cancer
- Health Systems, Economic Evaluations, Quality of Life
- Acute Myeloid Leukemia Research
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- Global Cancer Incidence and Screening
- Nutrition and Health in Aging
- DNA Repair Mechanisms
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research
- Chronic Myeloid Leukemia Treatments
- Economic and Financial Impacts of Cancer
- Pancreatic and Hepatic Oncology Research
- Cancer, Lipids, and Metabolism
- Vascular Tumors and Angiosarcomas
- Immune cells in cancer
- Medical Imaging Techniques and Applications
- Radiopharmaceutical Chemistry and Applications
University of Alabama at Birmingham
2020-2024
O'Neal Comprehensive Cancer Center
2020-2024
Baylor College of Medicine
2023-2024
Children's Cancer Center
2023
Roswell Park Comprehensive Cancer Center
2017-2022
University of Colorado Denver
2020-2021
University of Colorado Cancer Center
2020-2021
University of Florida
2019
Rutgers, The State University of New Jersey
2019
Rutgers Cancer Institute of New Jersey
2019
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely variants associated with increased risk breast, ovarian, pancreatic cancer recommended approaches to genetic testing/counseling management strategies in individuals these variants. This manuscript focuses BRCA-related breast/ovarian syndrome Li-Fraumeni syndrome. Carriers a BRCA1/2 variant have an excessive both breast ovarian that warrants...
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations genetic testing counseling hereditary cancer syndromes, risk management patients who are diagnosed with syndromes associated an increased of these cancers. panel meets at least annually to review comments, examine relevant new data, reevaluate update recommendations. These Insights summarize the panel’s discussion most recent regarding criteria high-penetrance genes breast...
Blacks tend to have a stronger inflammatory immune response than Whites. We hypothesized that racial differences in host immunity also manifest the tumor microenvironment, constituting part of distinct aggressive biology underlying higher mortality Black women.Pathological and gene expression profiling approaches were used for characterizing infiltrating cells breast microenvironment from 1315 patients Women's Circle Health Study. Racial phenotypes compared, with results validated publicly...
Persistent disparities in the burden of breast cancer between African Americans and White have been documented over many decades. Features characterizing American community include a 40% higher mortality rate, younger age distribution, greater advanced-stage increased risk biologically aggressive disease such as triple-negative phenotype, incidence male cancer. Public health experts, genetics researchers, clinical trialists, multidisciplinary oncology teams, advocates must collaborate to...
Acquired ESR1 mutations in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) drive treatment resistance and tumor progression; new strategies are needed. Lasofoxifene, a next-generation, oral, endocrine therapy tissue-specific ER antagonist, provided preclinical antitumor activity, alone or combined with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) ESR1-mutated mBC.In the open-label, phase II, ELAINE 2 trial (NCT04432454), women ESR1-mutated, ER+/human epidermal growth...
Angiogenesis is a hallmark of tumor development and metastatic progression, anti-angiogenic drugs targeting the VEGF pathway have shown to decrease disease progression in cancer patients. In this study, we analyzed anti-proliferative property plumbagin cisplatin sensitive, BRCA2 deficient, PEO-1 resistant, proficient PEO-4 ovarian cells. Both cells are sensitive irrespective status both normoxia hypoxia. Importantly, treatment effectively inhibits VEGF-A Glut-1 We also p53 mutant, OVCAR-5...
GAIP interacting protein C terminus (GIPC) is known to play an important role in a variety of physiological and disease states. In the present study, we have identified novel for GIPC as master regulator autophagy exocytotic pathways cancer. We show that depletion GIPC-induced pancreatic cancer cells, evident from upregulation marker LC3II. further report regulates cellular trafficking by modulating secretion, biogenesis, molecular composition exosomes. also involvement on metabolic stress...
Breast cancer (BC) patients experience increased stress with elevated cortisol levels, increasing risk of recurrence. Cortisol binds to a cytoplasmic receptor, glucocorticoid receptor (GR) encoded by GR gene (NR3C1). We hypothesized that not only cells, but even immune cells in the tumor microenvironment (TME) may contribute expression bulk and influence prognosis. To test this, mRNA data was accessed from METABRIC TCGA. “High” “low” based on highest lowest quartiles NR3C1 expression,...
Abstract We evaluate microsatellite instability-high (MSI-H) status with cell-free DNA (cfDNA) in metastatic breast cancer (MBC) and the association clinico-genomic characteristics. Patients MSI-H cfDNA (Guardant360 ® , 74 gene next-generation sequencing (NGS) MBC are identified. conduct a retrospective review. The median number of alterations maximum mutant allelic fraction (MAF) non-MSI-H cohorts compared Mann–Whitney U -test. Of 6718 patients ≥1 plasma NGS alteration, 42 (0.63%) have...
Multiple treatment options exist for patients with metastatic breast cancer (MBC). However, limited information is available on the impact of prior duration and class survival outcome novel therapies, such as cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+ HER2-) MBC.This study used a nationwide, de-identified electronic health record-derived database to identify women HR+ HER2- MBC who received at least one...
A 42-year-old African American female with chronic cocaine use for 20 years, presented two-day history of exertional shortness breath and pleuritic chest pain. She was admitted three years back acute kidney injury skin rashes. At that time, biopsy consistent leukocytoclastic vasculitis renal revealed proliferative glomerulonephritis. responded to oral prednisone mycophenolate complete recovery her functions. Skin rash waxing waning over the last two years. On second admission, patient found...
1081 Background: Racial disparity in breast cancer (BC) goes beyond access to care. Biology of HER2- and Triple Negative (TNBC) tumors has been shown differ between African Americans (AF) Caucasians (CF), contributing survival difference. Additionally, tumor infiltrating lymphocytes (TILs) incurred favorable response neoadjuvant therapy ER- TNBC. We hypothesized that TIL composition immune microenvironment (IME) differs AF CF, potentially explaining such biologic disparity. Methods: Using...
OBJECTIVES/GOALS: This study was performed to explore the capabilities of simultaneous [89 Zr]trastuzumab-PET/MRI acquisition in a cohort metastatic HER2+ breast cancer. The insights derived provide additional noninvasive characterization and precise intratumoral analysis tools for healthcare providers. METHODS/STUDY POPULATION: A total 13 patients, aged between 40 70, diagnosed with HER2-positive cancer, were selected participate this study. Whole-body Zr]trastuzumab-PET/MR imaging 5 ± 1...
Abstract BACKGROUND: Anti-HER2 therapies have transformed the trajectory for patients with HER2-positive (HER2+) MBC. A subset of HER2+ MBC do exceptionally well and remain on maintenance anti-HER2 therapy many years. However, current is non-curative are treated indefinitely. While these often well-tolerated, they may cause significant toxicities, expensive, typically require frequent infusion provider visits. Case reports retrospective series demonstrate that some after stopping treatment....
Abstract Introduction: Molecular imaging of human epidermal receptor 2 (HER2) aims to overcome limitations traditional HER2 assessment through biopsy, including invasiveness and inability detect intra inter-tumoral spatial heterogeneity. Prior studies suggest that [89Zr]Trastuzumab-positron emission tomography (PET) can effectively differentiate lesions (Dehdashti et al, Breast Cancer Res. Treat. 2018). Commonly, CT complements PET for anatomical reference, however, integrating MRI enables...
Abstract Background: Pre-clinical and clinical data suggest that CDK4/6 inhibitors can promote an immunogenic tumor microenvironment (TME) when combined with programmed cell death ligand 1 (PD-L1) synergistic anti-cancer effects are observed. To understand the differential of inhibition in context immunotherapy we designed a study evaluating neoadjuvant endocrine therapy (ET) PD-L1 inhibitor (avelumab) or without (palbociclib, palbo) patients (pts) stage II/III receptor (ER)-positive breast...
e23026 Background: Clinical trials (CTs) play a crucial role in expanding the landscape of breast cancer (BC) treatment, improving patient’s (pts) outcome and quality life. Success CTs relies heavily on pt recruitment. Understanding barriers for CT non-enrollment (NE) despite opportunities to enroll real world diverse populations can provide valuable insight into facilitators participation. Methods: Coordinators registered pts offered BC trial at O’Neal Comprehensive Cancer Center UAB...
Abstract Introduction Therapeutic clinical trials frequently lack diverse representation, hindering generalizability and exacerbating preexisting disparities in outcomes. This study explored associations between breast cancer patient demographics, trial eligibility, enrollment a National Cancer Institute (NCI)-designated center. Patients methods prospective cohort included patients with screened for therapeutic from July 2020 to January 2024. Eligibility was determined by the provider...
8521 Background: The role of EGFR tyrosine kinase inhibitors (TKIs) as adjuvant therapy in EGFR-mutated NSCLC is still controversial. Identifying biomarkers associated with increased risk recurrence may help stratify pts & guide therapy. We hypothesized that tumor immune microenvironment (TME) alterations could predict disease-free survival (DFS) these pts. Methods: Cancer Genome Atlas (TCGA) lung Adenocarcinoma (LUAD) data at Genomic Data Common (GDC) was accessed for pt phenotype,...
Abstract Purpose In nonmetastatic hormone receptor-positive and Her2-negative breast cancer, preoperative endocrine therapies can yield outcomes similar with chemotherapy. We evaluated the tolerability preliminary antitumor activity of letrozole, everolimus, carotuximab, a monoclonal antibody targeting endoglin, in cancer. Methods Eligible patients had newly diagnosed, stage 2 or 3, Her2/neu-negative Patients received escalating doses everolimus; dose letrozole carotuximab were fixed at 2.5...
Abstract Background. Patients (pts) with early triple negative breast cancer (eTNBC) are at increased risk of recurrence and death. Recent studies have focused on escalation therapy, current treatment standard least five drugs – associated toxicities - for eTNBC. Though presence residual disease after neoadjuvant therapy (NAT) as measured by burden (RCB) helps guide addition adjuvant treatment, more effective tools to tailor limited. Persistence circulating tumor DNA (ctDNA) in the setting...